This article is more than 5 years old. Information may no longer be current.

VIDEO: Drugs, devices bring ‘new era’ of glaucoma care

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA – “A new era of glaucoma management has arrived,” J. James Thimons, OD, said here at SECO. Thimons discussed how Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) relaxes the trabeculum and may provide some form of trabecular regeneration. He said Vyzulta (latanoprostene bunod ophthalmic solution 0.024%, Bausch + Lomb) has an additive effect to latanoprost acid by increasing vascular permeability and flow in and around the trabecular meshwork.

Thimons explained how these two new drugs, as well as new micro-invasive glaucoma surgery procedures, fit into the glaucoma patient care regimen.